|
시장보고서
상품코드
2003841
C1 에스테라제 억제제 시장 규모, 점유율 및 성장 분석 : 제품원별, 적응증별, 투여 경로별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)C1 Esterase inhibitor Market Size, Share, and Growth Analysis, By Product Source (Plasma-derived C1-INH, Recombinant C1-INH), By Indication, By Route of Administration, By End-User, By Region - Industry Forecast 2026-2033 |
||||||
세계의 C1 에스테라제 억제제 시장 규모는 2024년에 100억 달러로 평가되었고, 2025년 119억 달러에서 2033년에는 478억 5,000만 달러에 달하며 예측 기간(2026-2033년)에 CAGR 19.0%를 보일 전망입니다.
세계 C1 에스테라아제 억제제 시장은 보체 및 브라지키닌에 의한 혈관성 부종, 특히 유전성 혈관성 부종을 관리하기 위한 혈장 유래 및 재조합 치료제의 제공에 초점을 맞추었습니다. 이 분야는 적시 치료를 통해 생명을 위협하는 상황을 예방하고 환자의 생산성을 높이는 데 매우 중요한 역할을 하고 있으며, 그 결과 임상적, 경제적으로 큰 이점을 가져다주고 있습니다. 이 시장은 제한된 병원 내 혈장 주입에서 급성 발작과 장기 예방 모두를 위한 다양한 정맥 및 피하 투여 요법으로 진화하고 있으며, 베리나트(Berinert), 신라이즈(Cinryze), 해가르다(Haegarda), 재조합 루코네스트(Ruconest) 등의 제품이 그 예입니다.) 등의 제품이 그 예입니다. 시장 성장의 주요 촉진요인으로는 진단 기술 발전, 규제 지원 강화, 유전자 검사 정확도 향상 등을 꼽을 수 있습니다. 이를 통해 환자 집단을 확대하고 치료법에 대한 수요를 촉진할 수 있습니다. AI는 진단 정확도를 높이고, 치료 방침 결정을 지원함으로써 환자 개개인에 맞는 맞춤 치료를 가능하게 하고, 궁극적으로 시장의 효율성과 환자 결과를 개선할 수 있습니다.
세계 C1 에스테라아제 억제제 시장 성장 요인
의료진과 환자들 사이에서 C1 에스테라아제 억제제 치료에 대한 인식이 높아짐에 따라 적절한 적응증에 대한 사용이 확대되고 있으며, 이에 따라 수요가 증가하고 있습니다. 치료 프로토콜의 개선과 임상의들의 이해도가 높아짐에 따라 이러한 생물학적 제제를 처방할 때 확신을 가질 수 있게 되었습니다. 또한, 지원적인 가이드라인과 교육 활동을 통해 이러한 치료법이 의료 현장에 쉽게 적용될 수 있도록 돕고 있습니다. 그 결과, 조달 프로세스가 더욱 효율화되어 의료 시스템이 이러한 치료법을 약품 목록에 포함하도록 장려하고 있습니다. 이러한 채택 확대는 제조업체들이 공급을 늘리고 더 많은 발전을 위해 투자하도록 유도하여 시장 내 선순환을 만들어내고 있습니다.
세계 C1 에스테라아제 억제제 시장 성장 억제요인
세계 C1 에스테라아제 억제제 시장은 높은 도입 비용과 지속적인 치료 비용으로 인해 큰 제약에 직면해 있습니다. 이러한 경제적 부담은 의료 제공업체, 보험사, 환자의 접근을 제한할 뿐만 아니라 처방약 목록 등재에도 영향을 미치고 있습니다. 예산의 제약으로 인해 의료 기관은 비용 효율적인 치료법을 우선시하는 경우가 많으며, 그 결과 C1 에스테라아제 억제제의 사용은 특정 환자군에 국한되어 처방 행태가 변화하고 임상적 필요성이 인정되는 경우에도 광범위한 보급을 방해하고 있습니다. 또한, 이러한 경제적 어려움으로 인해 소규모 의료 서비스 제공업체들은 이러한 제품을 제공하는 것을 주저하고, 신중한 상환 전략을 채택하여 궁극적으로 성장과 시장 확장을 저해하고 있습니다.
세계 C1 에스테라아제 억제제 시장 동향
세계 C1 에스테라아제 억제제 시장은 치료의 편의성을 높이고 환자의 접근성을 확대하기 위해 재조합 제제 및 피하 투여 제제로의 전환이 두드러지고 있습니다. 제형의 안정성, 투약의 유연성, 첨단 전달 기술의 혁신으로 외래 및 재택 치료 옵션이 가능해져 환자 중심 치료에 대한 관심이 높아지는 추세에 부합합니다. 이러한 추세는 생명공학 기업과 의료기기 제조업체 간의 전략적 제휴를 촉진하고, 차세대 제품의 신속한 개발을 촉진하고 있습니다. 또한, 의료 보험사 및 의료 서비스 제공업체들은 의료 현장의 부담을 줄이면서 환자의 복약 순응도를 향상시키는 치료법에 점점 더 많은 관심을 기울이고 있으며, 이는 지속 가능한 치료 모델과 견고한 시장 성장을 뒷받침하는 지속적인 혁신을 촉진하고 있습니다.
자주 묻는 질문
목차
서론
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 C1 에스테라제 억제제 시장 규모 : 제품원별
세계의 C1 에스테라제 억제제 시장 규모 : 적응증별
세계의 C1 에스테라제 억제제 시장 규모 : 투여 경로별
세계의 C1 에스테라제 억제제 시장 규모 : 최종사용자별
세계의 C1 에스테라제 억제제 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
LSH 26.05.06Global C1 Esterase Inhibitor Market size was valued at USD 10.0 Billion in 2024 and is poised to grow from USD 11.9 Billion in 2025 to USD 47.85 Billion by 2033, growing at a CAGR of 19.0% during the forecast period (2026-2033).
The global C1 esterase inhibitor market focuses on providing plasma-derived and recombinant therapies to manage complement and bradykinin-mediated angioedema, particularly hereditary angioedema. This sector plays a crucial role in preventing life-threatening events and enhancing patient productivity through timely treatments, resulting in significant clinical and economic advantages. The market has evolved from limited hospital-based plasma infusions to a range of intravenous and subcutaneous therapies for both acute episodes and long-term prevention, illustrated by products such as Berinert, Cinryze, Haegarda, and recombinant Ruconest. Key drivers of market growth include advancements in diagnosis, increased regulatory support, and rising genetic testing accuracy, which boost identified patient populations and promote demand for therapies. AI facilitates personalized patient care by improving diagnostic accuracy and guiding treatment decisions, ultimately enhancing market efficiency and patient outcomes.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global C1 Esterase Inhibitor market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global C1 Esterase Inhibitor Market Segments Analysis
Global c1 esterase inhibitor market is segmented by product source, indication, route of administration, end-user and region. Based on product source, the market is segmented into Plasma-derived C1-INH and Recombinant C1-INH. Based on indication, the market is segmented into Prophylaxis of Hereditary Angioedema (HAE) and Acute HAE Attacks. Based on route of administration, the market is segmented into Intravenous (IV) Injection and Subcutaneous (SC) Injection. Based on end-user, the market is segmented into Specialized Immunology Clinics, Hospital Settings and Home Healthcare. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global C1 Esterase Inhibitor Market
The increasing recognition of C1 esterase inhibitor therapies among healthcare practitioners and patients is driving their broader use for suitable indications, thereby enhancing demand. Improved treatment protocols and greater familiarity among clinicians lead to more confidence in prescribing these biologic therapeutics. Additionally, supportive guidelines and educational efforts facilitate the integration of these therapies into healthcare practices. Consequently, procurement processes become more streamlined, prompting healthcare systems to include these treatments in their formularies. This growing adoption encourages manufacturers to increase supply and invest in further advancements, creating a positive feedback loop within the market.
Restraints in the Global C1 Esterase Inhibitor Market
The global C1 Esterase Inhibitor market faces significant constraints due to the high acquisition and continuous treatment costs associated with these therapies. Such financial burdens restrict access for healthcare providers, payers, and patients, while also influencing formulary placements. Budget limitations often lead institutions to favor more cost-effective treatments, resulting in the narrowed use of C1 esterase inhibitors to select patient populations, thereby altering prescribing behaviors and hindering widespread adoption even when clinical necessity exists. Additionally, these economic challenges deter smaller healthcare providers from offering these products and foster cautious reimbursement strategies, ultimately stifling growth and market expansion.
Market Trends of the Global C1 Esterase Inhibitor Market
The Global C1 Esterase Inhibitor market is witnessing a significant shift towards recombinant and subcutaneous formulations, enhancing treatment ease and expanding patient access. Innovations in formulation stability, dosing flexibility, and advanced delivery technologies are enabling outpatient and home treatment options, aligning with the growing preference for patient-centered care. This trend is fostering strategic collaborations between biotechnology firms and device manufacturers, facilitating the rapid development of next-generation products. Additionally, healthcare payers and providers are increasingly favoring therapies that alleviate the burden on care settings while improving patient adherence, thereby stimulating ongoing innovation that supports sustainable treatment models and robust market growth.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global C1 Esterase inhibitor Market Size by Product Source & CAGR (2026-2033)
- Market Overview
- Plasma-derived C1-INH
- Recombinant C1-INH
Global C1 Esterase inhibitor Market Size by Indication & CAGR (2026-2033)
- Market Overview
- Prophylaxis of Hereditary Angioedema (HAE)
- Acute HAE Attacks
Global C1 Esterase inhibitor Market Size by Route of Administration & CAGR (2026-2033)
- Market Overview
- Intravenous (IV) Injection
- Subcutaneous (SC) Injection
Global C1 Esterase inhibitor Market Size by End-User & CAGR (2026-2033)
- Market Overview
- Specialized Immunology Clinics
- Hospital Settings
- Home Healthcare
Global C1 Esterase inhibitor Market Size & CAGR (2026-2033)
- North America (Product Source, Indication, Route of Administration, End-User)
- US
- Canada
- Europe (Product Source, Indication, Route of Administration, End-User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Product Source, Indication, Route of Administration, End-User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Product Source, Indication, Route of Administration, End-User)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Product Source, Indication, Route of Administration, End-User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- CSL Behring
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Grifols
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Shire Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Takeda Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- BioMarin Pharmaceutical
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sobi
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Octapharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Genentech
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Apellis Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbbVie
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Alnylam Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ionis Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Amgen
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Vertex Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Regeneron Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eiger BioPharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Catalyst Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Emergent BioSolutions
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Conclusion & Recommendations
(주말 및 공휴일 제외)
